



GP 1614
Patent Application
Attorney Docket No. 10023A
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. Timothy
Greenamyre, et al.

Examiner: Not Yet
Assigned

APPLICATION NO.: 09/148,973

Group Art Unit: 1614

FILING DATE: September 4, 1998

TITLE: METHODS OF ADMINISTERING AN
AMPA RECEPTOR ANTAGONIST TO
TREAT DYSKINESIAS ASSOCIATED
WITH DOPAMINE AGONIST THERAPY

**I HEREBY CERTIFY THAT THIS
CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231
ON THIS 27 DAY OF January, 1999
BY Kristin A. Konrad**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed:

1. United States Patent, 5,654,303, Kornberg et al., August 5, 1997.
2. United States Patent, 5,639,751, Andrasi et al., June 17, 1997.
3. United States Patent, 5,614,532, Carling et al., March 25, 1997.
4. United States Patent, 5,606,062, Huff February 25, 1997
5. Albin R. L., Greenamyre J. T., (1992) Alternative Excitotoxic Hypothesis, Neurology, 42, pp. 733-737.
6. Greenamyre J. T., et al. (1994) Antiparkinsonian Effects of Remacemide Hydrochloride, A Glutamate Antagonist, in Rodent and Primate Models of

RECEIVED

FEB 2 1999

**MAIL ROOM
SERVICE CENTER**

Parkinson's Disease, Annals of Neurology, 35, pp. 655-661.

7. Greenamyre J. T. (1996) Pharmacological Pallidotomy with Glutamate Antagonists, Annals of Neurology, 39(5): pp. 557-558.
8. Klockgether T., Turski L., Honore T., et al. (1991) The Ampa Receptor Antagonist NBQX has Antiparkinsonian Effects in Monamine-depleted Rats and MPTP-Treated Monkeys, Annals of Neurology, 30, pp. 717-723, and;
9. Papa S. M. and Chase T. N. (1996) Levodopa-Induced Dyskinesias Improved by a Glutamate Antagonist in Parkinsonian Monkeys, Annals of Neurology, 39(5): pp. 574-578.

It is requested that the references listed above and on the attached form PTO-FB-A820 be carefully considered by the Examiner in accord with 37 CFR 1.104(a) and be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is believed necessary for filing the Information Disclosure Statement. However, if any fee is found necessary in connection with this Information Disclosure Statement, authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

January 27, 1999

Kristina L. Konstas
Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380